Innovations in manufacturing technologies, such as automation and closed systems, can enhance the scalability and cost-effectiveness of CAR T-cell therapy.
An overall survival (OS analysis of the phase 3 ZUMA-7 trial demonstrated longer OS in patients treated with axicabtagene ciloleucel (axi-cel) vs the standard of care for early relapsed or refractory (R/R) large B-cell lymphoma (LBCL).
The researchers emphasized the importance of early referral for chimeric antigen receptor (CAR) T-cell treatment, as patients eligible for the treatment are often in very late stages of disease, and mitigating delays in care has the potential to improve response rates by more than 10%.
Jason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.